 |
PRESS RELEASE
BurnsAdler
Pharmaceuticals, Inc. Licenses Nitrolingual® Pumpspray and
Nitronal®
IV Infusion from G. Pohl-Boskamp GmbH & Co.
Charlotte,
North Carolina – (June 17, 2003)
–
BurnsAdler Pharmaceuticals,
Inc. (“BurnsAdler”), an international pharmaceutical company,
announced today that they have entered into a seven year
licensing agreement with Pohl-Boskamp to market Nitrolingual®
Pumpspray® and Nitronal® IV Infusion throughout Latin
America. The company will launch and market both products
through local partners in over 10 countries. BurnsAdler will
market both the 60 and 200 dose bottles of Nitrolingual®
Pumpspray as well as the 50ml package of Nitronal® IV
Infusion. Nitrolingual® Spray is the market leader within the
sublingual segment of the nitroglycerin market in many major
markets including the United Kingdom, Canada, the United
States, Australia and Germany where it is marketed by Merck,
Aventis, First Horizon, Aventis and Pohl Boskamp,
respectively.
Banks Bourne, President of
BurnsAdler remarked, “We are pleased Pohl-Boskamp chose to
partner with our company in Latin America and are excited
about the market opportunity for these products. We believe
the expedited relief of chest pain, unique delivery mechanism,
and three year product shelf life, are just a few of the
reasons why patients will prefer Nitrolingual® Pumpspray over
nitroglycerin tablets for angina pectoris associated with
heart disease. These products make excellent additions to our
product portfolio and we look forward to a mutually beneficial
and long term alliance with Pohl-Boskamp.”
Nitrolingual® Pumpspray is a
sublingual spray of nitroglycerin used for the acute relief or
prevention of chest pain associated with angina pectoris that
results from heart disease. Pohl-Boskamp holds a patent that
was issued in 1993 on the formulation of Nitrolingual®. The
primary competitor to Nitrolingual® Pumpspray is short acting
nitroglycerin tablets. Unlike tablets, which have been shown
to lose their potency immediately upon opening the bottle,
Nitrolingual® Pumpspray maintains its potency for three
years. Further, studies have shown that the product provides
for more rapid absorption than the tablets. Each metered dose
of Nitrolingual® Pumpspray provides for consistent delivery of
nitroglycerin. Also, unlike the tablets, the product requires
less extensive storage and handling conditions. The American
College of
Cardiology/American Heart Association’s
Guidelines for the Management of Patients with Chronic Stable
Angina published in March 2000 recommends sublingual
nitroglycerin for the immediate relief of angina.
BurnsAdler is
an internationally focused
specialty pharmaceutical company that provides cost effective
product distribution and promotion for select emerging
pharmaceutical companies. BurnsAdler creates long term,
exclusive agreements which grant them the right to license,
supply and market products wherever their partners are
interested in generating additional revenue and profit. The
Company focuses on promoting products in
Europe,
South America, Latin America,
Far East, Canada and the Caribbean.
Pohl-Boskamp is a family owned
company in Germany, looking back to more than one hundred
years of experience to manufacture high-quality pharmaceutical
products. Early and continuous success comes from a line of
in-house developed cardiovascular products, with its main
products Nitrolingual® Spray (sublingual nitroglycerin) for
the use in angina pectoris and Nitronal® Aqueous Infusion, a
water-based infusion solution also containing nitroglycerin.
Pohl-Boskamp’s products, which are manufactured to the latest
international requirements, are exported to more than 40
countries and the company always strives to extend its success
to further markets and to establish long term business
relationships.
For additional
information about this news release contact Molly Whitehurst
at +1.704.770.0994 Ext 224. Find additional information about
BurnsAdler at
www.burnsadler.com.
|
BurnsAdler provides cost effective international product distribution and promotion for select emerging pharmaceutical companies.
 Print View
|
